Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

UNCY Unicycive Therapeutics, Inc.

Trading 01-21 13:07:30 EST

6.49

-0.09

-1.37%

High6.67	Low6.34	Vol214.14K
Open6.61	D1 Closing6.58	Amplitude4.97%
Mkt Cap139.48M	Tradable Cap84.42M	Total Shares21.49M
T/O1.40M	T/O Rate1.65%	Tradable Shares13.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"UNCY","market":"US","secType":"STK","nameCN":"Unicycive Therapeutics, Inc.","latestPrice":6.49,"timestamp":1769018773198,"preClose":6.58,"halted":0,"volume":214144,"delay":0,"changeRate":-0.013677811550151953,"floatShares":13007700,"shares":21491396,"eps":-1.602,"marketStatus":"Trading","change":-0.09,"latestTime":"01-21 13:07:30 EST","open":6.61,"high":6.6673,"low":6.3401,"amount":1395094.731072,"amplitude":0.049726,"askPrice":6.49,"askSize":356,"bidPrice":6.4,"bidSize":4686,"shortable":3,"etf":0,"ttmEps":-1.602,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769029200000},"marketStatusCode":2,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":6.58,"preHourTrading":{"tag":"盘前","latestPrice":6.58,"preClose":6.58,"latestTime":"09:02 EST","volume":742,"amount":4879.590114,"timestamp":1769004176563,"change":0,"changeRate":0,"amplitude":0.047112},"postHourTrading":{"tag":"盘后","latestPrice":6.55,"preClose":6.58,"latestTime":"18:53 EST","volume":1467,"amount":9619.0946,"timestamp":1768953227179,"change":-0.03,"changeRate":-0.004559,"amplitude":0.019347},"volumeRatio":0.580472,"impliedVol":1.3125,"impliedVolPercentile":0.6731},"requestUrl":"/m/hq/s/UNCY/wiki","defaultTab":"wiki","newsList":[{"id":"2601388971","title":"Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Plans in New Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601388971","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601388971?lang=en_us&edition=fundamental","pubTime":"2026-01-08 01:58","pubTimestamp":1767808733,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc. has published a corporate presentation detailing its diversified pipeline focused on novel treatments for kidney disease. The company's lead asset, oxylanthanum carbonate , is being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application  for OLC was resubmitted following progress in resolving FDA-cited deficiencies with a third-party manufacturing vendor, and a new PDUFA date is expected in the first half of 2026. Unicycive reports that OLC, if approved, will offer a smaller tablet that can be swallowed whole, distinguishing it from the reference-listed drug Fosrenol. The company also highlights ongoing development of UNI-494 for acute kidney injury. Unicycive states that recent developments in the reimbursement landscape have expanded the market opportunity for OLC, with the US market for hyperphosphatemia treatments estimated at over $1 billion. You can access the full presentation through ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDLbzgKG3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","UNCY"],"gpt_icon":0},{"id":"2595787536","title":"Unicycive Resubmits NDA for Oxylanthanum Carbonate to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2595787536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595787536?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:05","pubTimestamp":1767009908,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc. has resubmitted its New Drug Application  for oxylanthanum carbonate , an investigational oral phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, to the U.S. Food and Drug Administration . The resubmission follows significant progress by Unicycive's third-party manufacturing vendor in addressing FDA-cited deficiencies and demonstrating inspection readiness. The FDA previously identified a single deficiency related to the manufacturing vendor's compliance status. No additional issues were raised during a recent Type A meeting with the FDA. The company expects a new Prescription Drug User Fee Act  date in the first half of 2026, with review expected to be completed within six months of NDA acceptance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL5zb82S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","SG9999014013.SGD","IE00B64PRP62.GBP","SG9999014021.USD","LU2210150020.SGD","BK4112","LU2095319765.USD","BK4588","LU2210149790.SGD","IE00BKPKM429.USD","BK4539","SG9999014039.USD","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","UNCY","SG9999014005.SGD","NDAQ"],"gpt_icon":0},{"id":"2595787531","title":"Unicycive Therapeutics Inc - Nda Submission Review Expected Within 6 Months per Prescription Drug User Fee Act","url":"https://stock-news.laohu8.com/highlight/detail?id=2595787531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595787531?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:05","pubTimestamp":1767009900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA9SCFLH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UNCY","BK4139","BK4539"],"gpt_icon":0},{"id":"2595787530","title":"Unicycive Therapeutics Inc - Nda Resubmitted After Vendor Resolves FDA Deficiencies","url":"https://stock-news.laohu8.com/highlight/detail?id=2595787530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595787530?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:05","pubTimestamp":1767009900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA9SCFLH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UNCY","BK4139","BK4539"],"gpt_icon":0},{"id":"2595534787","title":"Unicycive Therapeutics Announces Resubmission of New Drug Application (Nda) for Oxylanthanum Carbonate (Olc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2595534787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595534787?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:05","pubTimestamp":1767009900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA9SCFLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UNCY","BK4539"],"gpt_icon":0},{"id":"2588065920","title":"Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588065920","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588065920?lang=en_us&edition=fundamental","pubTime":"2025-12-03 04:22","pubTimestamp":1764706977,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc. has released a corporate presentation detailing its current pipeline and development strategy in the field of kidney disease. The company's lead asset, oxylanthanum carbonate , is being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Unicycive plans to resubmit the New Drug Application  for OLC by the end of the year, following discussions with the FDA regarding the resolution of a previously identified manufacturing vendor compliance issue. If approved, OLC is expected to offer a lower pill burden compared to existing therapies, addressing a significant unmet need according to surveyed nephrologists. The company is also advancing UN-494, which is in development for the treatment of acute kidney injury and chronic kidney disease. Unicycive reports a cash runway extending into 2027 to support its ongoing clinical and commercial activities. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL3m38WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4139","BK4539"],"gpt_icon":0},{"id":"2586420654","title":"Unicycive Therapeutics to Participate in Upcoming Investor Events in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420654","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586420654?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:05","pubTimestamp":1764072300,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Nov.  25, 2025  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194215/0/en/Unicycive-Therapeutics-to-Participate-in-Upcoming-Investor-Events-in-December.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","ODD","BK4183","UNCY","BK4139","BK4539"],"gpt_icon":0},{"id":"2583349656","title":"Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2583349656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583349656?lang=en_us&edition=fundamental","pubTime":"2025-11-16 00:45","pubTimestamp":1763225119,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Unicycive Therapeutics and keeping the price target at $30.00. Jason McCarthy ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/unicycive-therapeutics-buy-rating-backed-by-promising-olc-progress-and-strategic-market-positioning-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/unicycive-therapeutics-buy-rating-backed-by-promising-olc-progress-and-strategic-market-positioning-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY","PRGS"],"gpt_icon":0},{"id":"2583890680","title":"Unicycive Therapeutics Doubles Stock Sale Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2583890680","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583890680?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:34","pubTimestamp":1763159660,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics ( ($UNCY) ) just unveiled an announcement. On November 14, 2025, Unicycive Therapeutics, Inc. amended its sales agreement wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/unicycive-therapeutics-doubles-stock-sale-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/unicycive-therapeutics-doubles-stock-sale-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY","BK4539","BK4139"],"gpt_icon":0},{"id":"2583268732","title":"BRIEF-Unicycive Therapeutics Increases ATM Offering To $100 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583268732","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583268732?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:13","pubTimestamp":1763158389,"startTime":"0","endTime":"0","summary":"BRIEF-Unicycive Therapeutics Increases ATM Offering To $100 Million - SEC FilingNov 14  - Unicycive Therapeutics Inc UNCY.O:UNICYCIVE THERAPEUTICS INC - INCREASES ATM OFFERING TO $100 MILLION - SEC FILINGSource text: [ID:n0001213900-25-111045]Further company coverage: UNCY.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UNCY","BK4539"],"gpt_icon":0},{"id":"2583568734","title":"Unicycive Therapeutics Inc - Increases Atm Offering to $100 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583568734","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583568734?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:12","pubTimestamp":1763158322,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","UNCY"],"gpt_icon":0},{"id":"2582759163","title":"Unicycive Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate, Cash And Cash Equivalents Totaled $42.7M, With Cash Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2582759163","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582759163?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:16","pubTimestamp":1762949800,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate, Cash And Cash Equivalents Totaled $42.7M, With Cash Runway Into 2027","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48799298/unicycive-therapeutics-q3-eps-0-46-beats-0-51-estimate-cash-and-cash-equivalents-totaled-42-7m-with","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"gpt_icon":0},{"id":"2582375564","title":"Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375564","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375564?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:10","pubTimestamp":1762949441,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc. has released a corporate presentation detailing updates on its pipeline of novel treatments for kidney disease. The company's lead asset, oxylanthanum carbonate , is being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The presentation notes that the company plans to resubmit the New Drug Application  for OLC by the end of 2025, following a Type A meeting with the FDA to address a single manufacturing-related deficiency identified in a previous review. No concerns were reported regarding pre-clinical, clinical, or safety data. If approved, OLC is expected to offer a lower pill burden for patients compared to existing phosphate binders. The company also highlights continued development of UNI-494 for acute kidney injury and chronic kidney disease. Unicycive reports a cash runway into 2027 to support its development and launch plans. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL48wYKC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","UNCY","BK4139"],"gpt_icon":0},{"id":"2582375836","title":"Unicycive Therapeutics reports Q3 results with $42.7 million cash and plans OLC NDA resubmission by year-end","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375836","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375836?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:05","pubTimestamp":1762949112,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc. reported a net loss attributable to common stockholders of $6.0 million for the three months ended September 30, 2025, compared to a net loss of $4.1 million for the same period in 2024. The increase was primarily due to higher labor and professional services costs, as well as a change in the fair value of warrant liability. As of September 30, 2025, cash and cash equivalents totaled $42.7 million, with the company expecting its cash runway to extend into 2027. During the period, Unicycive announced it remains on track to resubmit the New Drug Application for oxylanthanum carbonate by year-end, following discussions with the FDA regarding a previously noted manufacturing deficiency. The company also presented new data indicating a reduced pill burden for its product compared to existing phosphate binders.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL31lBj8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","BK4588","LU0314104364.USD","IE00BGHQF748.EUR","BK4539","IE00B3QW5Z07.USD","BK4139","IE00B64PRP62.GBP","LU2210150020.SGD","UNCY","NDAQ","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582373039","title":"Unicycive Therapeutics Inc - on Track to Resubmit Nda for Oxylanthanum Carbonate by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373039?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:05","pubTimestamp":1762949100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX126343:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UNCY","BK4139","BK4539"],"gpt_icon":0},{"id":"2579511721","title":"Unicycive Therapeutics Reports Oxylanthanum Carbonate Cuts Pill Burden in Hyperphosphatemia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2579511721","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579511721?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:06","pubTimestamp":1761822368,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc. has announced that new data from its open-label pivotal trial of oxylanthanum carbonate , an investigational phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease  patients on dialysis, will be presented at the American Society of Nephrology  Kidney Week 2025, scheduled for November 5-9, 2025, in Houston, TX. The study enrolled 86 CKD patients on dialysis and found that treatment with OLC led to a significant reduction in pill burden, with both pill volume and pill count decreased compared to previous phosphate binder therapy. Additionally, serum phosphate levels of ≤5.5 mg/dL were achieved in 91% of patients at the end of the OLC titration period. These results will be detailed in a poster session at the upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL946rqh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","BK4588","BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","LU0314104364.USD","UNCY","BK4539","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2579115783","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), United Therapeutics (UTHR) and Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2579115783","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579115783?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:50","pubTimestamp":1761817817,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bausch + Lomb Corporation (BLCO – Research Report)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-bausch-lomb-corporation-blco-united-therapeutics-uthr-and-unicycive-therapeutics-uncy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-bausch-lomb-corporation-blco-united-therapeutics-uthr-and-unicycive-therapeutics-uncy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","XBI","BK4539","BLCO","HCSG","BK4198","BK4588","BK4532","LU0029874061.USD","UTHR","LU1699723380.USD","UNCY","BK4137","BK4139","LU1571399168.USD","BK4581","XLV","LU0128526141.USD"],"gpt_icon":0},{"id":"2579600139","title":"Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Development Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2579600139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579600139?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:39","pubTimestamp":1761770372,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc. has released a corporate presentation outlining its progress in developing novel treatments for kidney disease. The company's lead asset, oxylanthanum carbonate , is being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Unicycive plans to resubmit the New Drug Application  for OLC by the end of the year, following a recent FDA meeting that addressed a manufacturing-related deficiency. No other concerns were identified by the FDA regarding the clinical or safety data submitted. If approved, OLC would offer a smaller, swallowable tablet as compared to the reference drug Fosrenol, aiming to address the significant issue of pill burden among patients. The company reports a cash runway into 2027 to support the NDA resubmission, potential approval, and commercial launch of OLC. Additional pipeline programs include UNI-494 for acute kidney injury and chronic kidney disease. You can access the full presentation throug","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL4sF7s1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","UNCY"],"gpt_icon":0},{"id":"2579118430","title":"Guggenheim Sticks to Its Buy Rating for Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579118430?lang=en_us&edition=fundamental","pubTime":"2025-10-30 01:45","pubTimestamp":1761759926,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Vamil Divan reiterated a Buy rating on Unicycive Therapeutics yesterday and set a price target of $50.00. The company’s shares o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-unicycive-therapeutics-uncy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-unicycive-therapeutics-uncy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"gpt_icon":0},{"id":"2579091972","title":"Unicycive Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2579091972","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579091972?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:17","pubTimestamp":1761736620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2025 07:17 ET (11:17 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unicycive.com","stockEarnings":[{"period":"1week","weight":0.0912},{"period":"1month","weight":0.1835},{"period":"3month","weight":0.3456},{"period":"6month","weight":0.3567},{"period":"1year","weight":0.0613},{"period":"ytd","weight":0.1404}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.056996},{"month":2,"riseRate":0.5,"avgChangeRate":0.069909},{"month":3,"riseRate":0.5,"avgChangeRate":0.758664},{"month":4,"riseRate":0.25,"avgChangeRate":-0.190246},{"month":5,"riseRate":0.5,"avgChangeRate":-0.066545},{"month":6,"riseRate":0,"avgChangeRate":-0.181228},{"month":7,"riseRate":0,"avgChangeRate":-0.103059},{"month":8,"riseRate":0.2,"avgChangeRate":-0.122604},{"month":9,"riseRate":0.6,"avgChangeRate":0.038818},{"month":10,"riseRate":0.8,"avgChangeRate":0.050976},{"month":11,"riseRate":0.6,"avgChangeRate":0.060673},{"month":12,"riseRate":0.4,"avgChangeRate":0.09852}],"exchange":"NASDAQ","name":"Unicycive Therapeutics, Inc.","nameEN":"Unicycive Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Unicycive Therapeutics, Inc.,UNCY,Unicycive Therapeutics, Inc.股票,Unicycive Therapeutics, Inc.股票老虎,Unicycive Therapeutics, Inc.股票老虎国际,Unicycive Therapeutics, Inc.行情,Unicycive Therapeutics, Inc.股票行情,Unicycive Therapeutics, Inc.股价,Unicycive Therapeutics, Inc.股市,Unicycive Therapeutics, Inc.股票价格,Unicycive Therapeutics, Inc.股票交易,Unicycive Therapeutics, Inc.股票购买,Unicycive Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction